» Articles » PMID: 7324176

Cardiomyopathy of Doxorubicin in Experimental Animals, Factors Affecting the Severity, Distribution and Evolution of Myocardial Lesions

Overview
Journal Tumori
Publisher Sage Publications
Specialty Oncology
Date 1981 Oct 31
PMID 7324176
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Heart lesions induced in mice, rats, rabbits and dogs by Doxorubicin administered i.v. according to various schedules were studied by light and electron microscopy Vacuolization of myocardial cytoplasm due to distention of the sarcoplasmic reticulum, the T-tubule system and the Golgi vesicles was one of the most common findings. Myocytolysis, clumping and loss of fibrils, fragmentation of sarcomeres, swelling of mitochondria and an increase in lysosomes and residual bodies were also observed. The severity of the cardiomyopathy, quantitatively evaluated by a score system, proved to be dose-dependent. Cardiomyopathy was more severe when the treatment was given in a short period by administration of high doses than when the same cumulative dose was administered as low doses repeated for a long period. The left atrium was more severely affected than the ventricles when high doses were given, whereas it was less affected in animals given low doses. The cardiomyopathy was less severe in animals receiving the same dose in a high volume of solvent and during a long perfusion time. Threshold doses were needed both to induce the cardiomyopathy and to establish it as a progressive disease.

Citing Articles

Spontaneously occurring cardiovascular lesions in commonly used laboratory animals.

Herman E, Eldridge S Cardiooncology. 2020; 5:6.

PMID: 32154013 PMC: 7048038. DOI: 10.1186/s40959-019-0040-y.


Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy.

Silva Dos Santos D, Visconde Brasil G, Ramos I, Mesquita F, Kasai-Brunswick T, Christie M Stem Cell Res Ther. 2018; 9(1):30.

PMID: 29402309 PMC: 5799903. DOI: 10.1186/s13287-018-0788-2.


Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification.

Li D, Wang Z, Ding G, Tan W, Luo X, Criollo A Circulation. 2016; 133(17):1668-87.

PMID: 26984939 PMC: 4856587. DOI: 10.1161/CIRCULATIONAHA.115.017443.


Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Rahman A, Yusuf S, Ewer M Int J Nanomedicine. 2008; 2(4):567-83.

PMID: 18203425 PMC: 2676818.


Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Jain D J Nucl Cardiol. 2000; 7(1):53-62.

PMID: 10698235 DOI: 10.1067/mnc.2000.103324.